{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:36:54Z","timestamp":1793385414582,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.canlet.2024.216993","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T15:58:22Z","timestamp":1716652702000},"page":"216993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor"],"prefix":"10.1016","volume":"596","author":[{"given":"Zeta","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Cheol","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-8075","authenticated-orcid":false,"given":"Jennifer T.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahide","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Courtney M.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-7874","authenticated-orcid":false,"given":"Lowell","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-2638","authenticated-orcid":false,"given":"Eddy S.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Mark","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-9122","authenticated-orcid":false,"given":"Piotr","family":"Rychahou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216993_bib1","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1210\/jc.2003-031575","article-title":"Non-islet origin of pancreatic islet cell tumors","volume":"89","author":"Vortmeyer","year":"2004","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.canlet.2024.216993_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.canlet.2024.216993_bib3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177 Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2024.216993_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000434723","article-title":"Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy","volume":"103","author":"Claringbold","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.canlet.2024.216993_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.biochem.67.1.71","article-title":"Ribonucleotide reductases","volume":"67","author":"Jordan","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2024.216993_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/bies.950150507","article-title":"DNA damage and cell cycle regulation of ribonucleotide reductase","volume":"15","author":"Elledge","year":"1993","journal-title":"Bioessays"},{"key":"10.1016\/j.canlet.2024.216993_bib7","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216993_bib8","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/sj.bjc.6604344","article-title":"Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel\/gemcitabine","volume":"98","author":"Souglakos","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216993_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003695","article-title":"Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients","volume":"3","author":"Boukovinas","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216993_bib10","first-page":"1328","article-title":"Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells","volume":"55","author":"Zhou","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216993_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216308","article-title":"Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1","author":"Corrales-Guerrero","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216993_bib12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.ijrobp.2020.07.2322","article-title":"Osalmid, a novel identified RRM2 inhibitor, enhances radiosensitivity of esophageal cancer","volume":"108","author":"Tang","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2024.216993_bib13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1535-7163.MCT-05-0384","article-title":"A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase","volume":"5","author":"Shao","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2024.216993_bib14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0006-2952(99)00419-0","article-title":"Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity","volume":"59","author":"Finch","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216993_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"Kunos","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2024.216993_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10637-007-9066-3","article-title":"A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium","volume":"25","author":"Mackenzie","year":"2007","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2024.216993_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10637-007-9085-0","article-title":"A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine\u00ae) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells","volume":"26","author":"Ma","year":"2008","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2024.216993_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0016-5085(91)90004-5","article-title":"Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth","volume":"101","author":"Evers","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.216993_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11010-009-0165-7","article-title":"QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells","volume":"331","author":"Doihara","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.canlet.2024.216993_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/1541-7786.MCR-17-0163","article-title":"Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model","volume":"16","author":"Benten","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216993_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/cells10051261","article-title":"PI3K\/mTOR dual inhibitor PF-04691502 is a schedule-dependent radiosensitizer for gastroenteropancreatic neuroendocrine tumors","volume":"10","author":"Chow","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.216993_bib22","article-title":"Impact of backscatter material thickness on the depth dose of orthovoltage irradiators for radiobiology research","volume":"64","author":"Chen","year":"2019","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.canlet.2024.216993_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102123","article-title":"Peroxiredoxin IV plays a critical role in cancer cell growth and radioresistance through the activation of the Akt\/GSK3 signaling pathways","volume":"298","author":"Ding","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2024.216993_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.147840","article-title":"Extracellular vesicles released after cranial radiation: an insight into an early mechanism of brain injury","volume":"1782","author":"Sukati","year":"2022","journal-title":"Brain Res."},{"key":"10.1016\/j.canlet.2024.216993_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/01.sla.0000220040.66012.a9","article-title":"Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma","volume":"243","author":"Rychahou","year":"2006","journal-title":"Ann. Surg."},{"key":"10.1016\/j.canlet.2024.216993_bib26","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod. Pathol.: Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.canlet.2024.216993_bib27","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/cells9051253","article-title":"Targeting PI3K and AMPK\u03b1 signaling alone or in combination to enhance radiosensitivity of triple negative breast cancer","volume":"9","author":"Johnson","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.216993_bib28","unstructured":"G-Biosciences, CytoScanTM SRB Cell Cytotoxicity Assay."},{"key":"10.1016\/j.canlet.2024.216993_bib29","unstructured":"Beckman Coulter, Cell Cycle Staining Protocol."},{"key":"10.1016\/j.canlet.2024.216993_bib30","series-title":"Annexin V Staining Protocol","year":"2023"},{"key":"10.1016\/j.canlet.2024.216993_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2018.02.008","article-title":"Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles","volume":"275","author":"Rychahou","year":"2018","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2024.216993_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13578-020-0376-x","article-title":"ATM, ATR and DNA-PKcs kinases\u2014the lessons from the mouse models: inhibition \u2260 deletion","volume":"10","author":"Menolfi","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.canlet.2024.216993_bib33","article-title":"Efficacy of everolimus combined with 177Lu-dotatate in the treatment of neuroendocrine tumors","author":"Aljubran","year":"2022","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.canlet.2024.216993_bib34","doi-asserted-by":"crossref","first-page":"35991","DOI":"10.1074\/jbc.274.50.35991","article-title":"Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication","volume":"274","author":"Abid","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2024.216993_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-10-19","article-title":"Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer","volume":"10","author":"Satheesha","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2024.216993_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1146\/annurev-biochem-060614-034335","article-title":"Mechanisms of ATM activation","volume":"84","author":"Paull","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2024.216993_bib37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2024.216993_bib38","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1172\/JCI31604","article-title":"Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis","volume":"117","author":"Eaton","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216993_bib39","doi-asserted-by":"crossref","first-page":"26009","DOI":"10.1074\/jbc.272.41.26009","article-title":"Heat shock transcription factor 1 binds selectively in vitro to Ku protein and the catalytic subunit of the DNA-dependent protein kinase","volume":"272","author":"Huang","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2024.216993_bib40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bcp.2006.11.014","article-title":"Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress","volume":"73","author":"Lin","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216993_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110996","article-title":"Inhibiting RRM2 to enhance the anticancer activity of chemotherapy","volume":"133","author":"Zhan","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2024.216993_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216993_bib43","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/carcin\/bgg137","article-title":"ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses","volume":"24","author":"Yang","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2024.216993_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM\u2013Chk2 and ATR\u2013Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216993_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216308","article-title":"Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1","volume":"570","author":"Corrales-Guerrero","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216993_bib46","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.2307\/3579807","article-title":"The role of DNA single-and double-strand breaks in cell killing by ionizing radiation","volume":"150","author":"Olive","year":"1998","journal-title":"Radiat. Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524003872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T21:05:55Z","timestamp":1718399155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524003872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":46,"alternative-id":["S0304383524003872"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216993","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"216993"}}